02186 LUYE PHARMA
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2025) | |||
| Current | 1.53X | Oper Margin | 26.4% |
|---|---|---|---|
| LT Debt/Equity | 16.9% | Net Margin | 9.8% |
| Total Debt/Equity | 58.6% | Return on Equity | 3.9% |
| Price/Book | 0.65X | Return on Assets | 1.9% |
| (HKD 2.920) | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
| Net Profit (MHKD) | 688.73 | 501.85 | 587.04 | 678.11 | -164.37 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | +37.2 | -14.5 | -13.4 | +512.5 | -119.6 |
| Earnings Per Share (HKD) | 0.177 | 0.133 | 0.158 | 0.195 | -0.048 |
| Earnings Per Share Growth (%) | +32.5 | -15.3 | -19.2 | +508.4 | -118.1 |
| Dividend Per Share (HKD) | No dividend | No dividend | No dividend | No dividend | No dividend |
| P/E* (X) | 16.52 | 21.89 | 18.54 | 14.99 | N/A |
| Yield (%) | N/A | N/A | N/A | N/A | N/A |
| Dividend Share (%) | N/A | N/A | N/A | N/A | N/A |
| Book NAV (HKD) | 4.479 | 4.002 | 3.672 | 3.214 | 2.932 |
| Auditors' Opinion | N/A | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2026-04-02 21:40:20
Latest Result
| (RMBMn) | 2025-12 | 2024-12 | Chg* (%) | 2023-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 6,308 | 6,061 | +4.1 | 6,143 |
| Operating Result | 976.206 | 821.505 | +18.8 | 697.806 |
| Associates | -31.569 | -0.774 | +3,978.7 | 0.794 |
| Profit Before Taxation | 944.637 | 839.219 | +12.6 | 700.1 |
| Taxation | 238.978 | 194.211 | +23.1 | 161.023 |
| Profit /( Loss) After Taxation | 705.659 | 645.008 | +9.4 | 539.077 |
| Minority Interests | 86.912 | 173.122 | -49.8 | 6.472 |
| Net Profit | 618.747 | 471.886 | +31.1 | 532.605 |
| Earnings Per Share () | 0.1768 | 0.1334 | +32.5 | 0.1575 |
| Announcement Date | 2026-03-31 | 2025-03-30 | NA | 2024-03-27 |
* Annualised
Last Update Time: 2026-04-02 21:40:25
